Liposomes are lipid bilayer vesicles that are utilized to transport chemicals to particular locations within the body. They can encapsulate both hydrophilic and lipophilic medicines. Since their development, liposomes have been the focus of in-depth research on medication delivery and are thought to be the most effective type of nanocarrier. Liposomes are superior to typical drug delivery systems in that they have site-targeting, controlled or prolonged release, protection against drug degradation and clearance, better therapeutic effects, and less harmful side effects. Compared to conventional small molecule medications and biologics, liposomal formulations confront significantly more characterisation and regulatory review hurdles since they are an inherently complex delivery method. The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) now offer regulatory guidelines for new liposomal drug application evaluations as a result of the rapid development of liposomal drugs. Liposomal drugs are categorized as complex drug products by the FDA in the United States, meaning that they must follow particular regulatory guidelines covering formulation, manufacturing, and clinical evaluation. The European Medicines Agency (EMA) handles liposome drug products in the same way, emphasizing the need for comprehensive characterization and validation. This study presents a thorough analysis of the regulatory environment surrounding the development of liposome drugs, emphasizing the crucial elements of compliance with US and EU regulations.
Subedar et al. (Fri,) studied this question.